Ewing Weight Loss Clinic

Leading Injectable Weight Loss Medications

Ewing Weight Loss Clinic in Reno offers prescriptions for Tirzepatide and Semaglutide based weight loss drugs.

• Zepbound & Mounjaro (Tirzepatide) – Eli Lilly
  • Mechanism: Dual GIP and GLP-1 receptor agonist.
  • Efficacy: Average weight loss of ~25% over one year.
  • Notes: Approved for type 2 diabetes and obesity; considered most effective injectable option currently available.
• Wegovy & Ozempic (Semaglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 15–17% over 68 weeks.
  • Notes: Widely prescribed; an oral version has been submitted for FDA approval.
• Saxenda (Liraglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 5–7% over one year.
  • Notes: Administered daily; less potent than newer options.

Available at Ewing Weight Loss Clinic, GLP-1 receptor agonists, including Tirzepatide and Semaglutide, are effective for accelerated weight loss to achieve optimal personal health. Contact Us for details, or call: 775-322-3011.

Leading Oral Weight Loss Medications

• Rybelsus (Oral Semaglutide) – Novo Nordisk
  • Mechanism: GLP-1 receptor agonist.
  • Efficacy: Average weight loss of 15.1% over 68 weeks at a 50mg dose.
  • Notes: Currently approved for type 2 diabetes; higher-dose version submitted for FDA approval for weight loss.
• Orforglipron – Eli Lilly (Experimental)
  • Mechanism: Oral, non-peptide GLP-1 receptor agonist.
  • Efficacy: Demonstrated significant weight loss in Phase 3 trials for type 2 diabetes patients.
  • Notes: Still in clinical trials; offers a needle-free alternative.
• Contrave (Naltrexone/Bupropion)
  • Mechanism: Targets appetite and cravings.
  • Efficacy: Over 40% of users lose at least 5% of body weight within a year.
  • Notes: Especially useful for emotional eating.
• Qsymia (Phentermine/Topiramate ER)
  • Mechanism: Combines appetite suppression and satiety enhancement.
  • Efficacy: Approximately 70% of users lose at least 5% of body weight within a year.
  • Notes: Controlled substance; not recommended for individuals with certain health conditions.
• Orlistat (Xenical)
  • Mechanism: Blocks fat absorption.
  • Efficacy: 35% of users lose at least 5% of body weight over a year.
  • Notes: Available over-the-counter as Alli; may cause gastrointestinal side effects.

Emerging Treatments / In-Development

• Retatrutide – Eli Lilly
  • Mechanism: Triple agonist targeting GLP-1, GIP, and glucagon receptors.
  • Efficacy: Average weight loss of 24% in clinical trials.
  • Status: In Phase 3 trials; not yet FDA-approved.
• CagriSema (Cagrilintide/Semaglutide) – Novo Nordisk
  • Mechanism: Combination of amylin and GLP-1 receptor agonists.
  • Efficacy: Average weight loss of 20.4% over 68 weeks.
  • Status: In Phase 3 trials; not yet FDA-approved.